SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma

Sakai, Naoki; M, Baba; Nagasima, Yoji; Kato, Yukio; Hirai, Kohtaro; Kondo, Keiichi; Kobayashi, Kazuki; Yoshida, Minoru; Kaneko, Shotaro; Kishida, Takeshi; Kawakami, Satoshi; Hosaka, Masahiko; Inayama, Yoshiaki; Yao, Masahiro

doi:10.1053/hupa.2001.28244

Cited by 45 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with lower SPARC expression had an improved prognosis. A similar clinicpathologic relationship between SPARC expression and tumour progression has been reported in other malignancies (Porte et al, 1995;Massi et al, 1999;Thomas et al, 2000;Sakai et al, 2001;Yamanaka et al, 2001;Yamashita et al, 2003). The expression of SPARC has been positively correlated with the histological grade of tumour cells in bladder cancer, thyroid cancer, glioma and HCC (Le Bail et al, 1999;Menon et al, 2000;Takano et al, 2000;Yamanaka et al, 2001).…”

Section: Discussionmentioning

confidence: 49%

“…The expression of SPARC has been positively correlated with the histological grade of tumour cells in bladder cancer, thyroid cancer, glioma and HCC (Le Bail et al, 1999;Menon et al, 2000;Takano et al, 2000;Yamanaka et al, 2001). Higher SPARC expression was also associated with local tumour invasion in colorectal, breast, bladder and renal cell carcinoma (Porte et al, 1995;Sakai et al, 2001;Yamanaka et al, 2001;Iacobuzio-Donahue et al, 2002). Increased levels of SPARC were associated with lymph node metastasis in colorectal and oesophageal cancers, liver metastasis in colorectal cancer and bone metastasis in prostate cancers (Porte et al, 1995;Thomas et al, 2000;Yamashita et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…One of SPARC's biological functions is the modulation of angiogenesis (Lane et al, 1994). It may promote neo-vascularisation, invasion and metastasis of human malignancies (Motamed, 1999;Paley et al, 2000;Thomas et al, 2000;Sakai et al, 2001). Furthermore, SPARC has demonstrated antiadhesive properties and displayed diminished adhesive interactions between tumour cells and the extracellular matrix via the reduction of cell -substrate contacts and the promotion of cytoskeletal rearrangement (Ledda et al, 1997).…”

Section: Discussionmentioning

confidence: 99%

“…Initially in 1981, SPARC was described as a bone matrix protein involved in bone mineralisation. Recent studies have revealed other biological functions including cell proliferation , migration, morphogenesis (Strandjord et al, 1995), deadhesion, antiproliferation (Motamed,including melanoma, glioma, meningioma, colorectal, breast, oesophageal, renal cell, prostate, bladder and hepatocellular carcinoma (Porte et al, 1995;Le Bail et al, 1999;Massi et al, 1999;Menon et al, 2000;Takano et al, 2000;Thomas et al, 2000;Sakai et al, 2001;Yamanaka et al, 2001;Iacobuzio-Donahue et al, 2002;Yamashita et al, 2003). However, SPARC was repressed in ovarian cancer (Paley et al, 2000).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance

et al. 2004

Br J Cancer

104

View full text Add to dashboard Cite

Gastric cancer is the second most common cancer in the world and the fifth leading cause of cancer-related death in Taiwan. To improve the survival of gastric cancer patients, biomarkers for early detection and effective anticancer therapy are required. An essential first step is to profile gene expression in gastric cancer and identify genes that are aberrantly expressed, and to do this cDNA microarrays were performed. The clinic -pathologic correlation and prognostic significance of the aberrantly expressed genes were evaluated to identify novel biomarkers of gastric cancer. Fresh surgical samples of tumour tissue and matching noncancerous mucosa were obtained immediately after gastric resection in 43 patients. Secreted Protein, Acidic and Rich in Cysteine (SPARC) (Osteonectins), one of the most highly expressed genes in both intestinal and diffuse gastric cancers in our microarray results, was selected for further study. The overexpression of SPARC was verified using real-time quantitative-reverse transcription -polymerase chain reaction (Q-RT -PCR), Northern blot and immunohistochemical staining. The expression of SPARC in tumour tissues was, on average, 4.27-fold increased (95% CI 2.68 -5.85) compared to adjacent noncancerous mucosa (Po0.001). The expression of SPARC was higher in advanced (T2, T3 and T4) cancer compared to the early (T1) cancer (P ¼ 0.048) with regard to depth of wall invasion. Higher expression of SPARC was significantly associated with lymph node metastasis (Po0.001), lymphatic invasion (P ¼ 0.004) and perineural invasion (P ¼ 0.047). Expression of SPARC in patients in stage II and above was significantly higher than those in stage I (P ¼ 0.017). The 3-year survival of patients with lower expression of SPARC was significantly better than those with a higher expression (log rank P ¼ 0.047). These data indicate the potential of SPARC as a prognostic marker for gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance

et al. 2004

Br J Cancer

104

View full text Add to dashboard Cite

show abstract

“…However, in situ hybridization has demonstrated the high expression of SPARCL1 in angiogenic endothelial cells in the stromal areas of invasive pancreatic adenocarcinoma (15). Moreover, SPARC genes have been found overexpressed in melanomas (16) and renal carcinoma (17). Additionally, in colorectal carcinoma, where SPARCL1 was found highly expressed, its upregulation appeared to act as a pro-angiogenic stimulus (18).…”

Section: Discussionmentioning

confidence: 99%

SPARC-like1 mRNA is overexpressed in human uterine leiomyoma

Mencalha

Levinsphul²,

Deterling³

et al. 2008

Mol Med Report

View full text Add to dashboard Cite

Abstract. Uterine leiomyomas (ULs), also known as fibroids, are benign and monoclonal tumors frequently found in the female population. The genetic alterations that contribute to UL tumor development have not been well established, and the goal of this study was to reveal gene expression variation between ULs and healthy uterine tissue. We compared the gene expression profiles of 13 UL tumors with that of their adjacent normal tissue using the Differential Display mRNA assay (DDRT-PCR). Among the genes upregulated in some of the UL samples, several genes previously described in the context of cancer were identified, namely LIMK1, MCM3 and UHRF1. In addition, we identified a cDNA present in UL samples from distinct patients, which was absent from their normal tissue. Direct sequencing of this cDNA revealed a human SPARC-like1 (SPARCL1) mRNA homology. Through semi-quantitative PCR, we demonstrated that SPARCL1 was upregulated in approximately 77% of UL samples, but was absent in normal tissue. Real-time PCR (QPCR) revealed that SPARCL1 expression was increased 5-fold in ULs compared to adjacent normal tissue. These results suggest that the SPARCL1 gene is involved in UL development.

show abstract

Identification of SPARC as a candidate target antigen for immunotherapy of various cancers

Inoue

Senju

Hirata

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

To establish efficient anticancer immunotherary, it is important to identify tumor‐associated antigens (TAAs) directing the immune system to attack cancer. A genome‐wide cDNA microarray analysis identified that secreted protein acidic and rich in cysteine (SPARC) gene is overexpressed in the gastric, pancreatic and colorectal cancer tissues but not in their noncancerous counterparts. This study attempted to identify HLA‐A24 (A*2402)‐restricted and SPARC‐derived CTL epitopes. We previously identified H‐2Kd‐restricted and SPARC‐derived CTL epitope peptides in BALB/c mice, of which H‐2Kd‐binding peptide motif is comparable with that of HLA‐A24 binding peptides. By using these peptides, we tried to induce HLA‐A24 (A*2402)‐restricted and SPARC‐reactive human CTLs and demonstrated an antitumor immune response. The SPARC‐A24‐1143–151 (DYIGPCKYI) and SPARC‐A24‐4225–234 (MYIFPVHWQF) peptides‐reactive CTLs were successfully induced from peripheral blood mononuclear cells by in vitro stimulation with these two peptides in HLA‐A24 (A*2402) positive healthy donors and cancer patients, and these CTLs exhibited cytotoxicity specific to cancer cells expressing both SPARC and HLA‐A24 (A*2402). Furthermore, the adoptive transfer of the SPARC‐specific CTLs could inhibit the tumor growth in nonobese diabetic/severe combined immunodeficient mice bearing human cancer cells expressing both HLA‐A24 (A*2402) and SPARC. These findings suggest that SPARC is a potentially useful target candidate for cancer immunotherapy.

show abstract

SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma

Cited by 45 publications

References 31 publications

Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance

Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance

SPARC-like1 mRNA is overexpressed in human uterine leiomyoma

Identification of SPARC as a candidate target antigen for immunotherapy of various cancers

Contact Info

Product

Resources

About